Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Multiple genetic variants predict steady-state nevirapine clearance in HIV-infected Cambodians.

Bertrand J, Chou M, Richardson DM, Verstuyft C, Leger PD, Mentré F, Taburet AM, Haas DW; ANRS 12154 Study Group.

Pharmacogenet Genomics. 2012 Dec;22(12):868-76. doi: 10.1097/FPC.0b013e32835a5af2.

2.

Population pharmacokinetic-pharmacogenetic study of nevirapine in HIV-infected Cambodian patients.

Chou M, Bertrand J, Segeral O, Verstuyft C, Borand L, Comets E, Le Tiec C, Becquemont L, Ouk V, Mentre F, Taburet AM.

Antimicrob Agents Chemother. 2010 Oct;54(10):4432-9. doi: 10.1128/AAC.00512-10. Epub 2010 Aug 9.

3.

Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals.

Heil SG, van der Ende ME, Schenk PW, van der Heiden I, Lindemans J, Burger D, van Schaik RH.

Ther Drug Monit. 2012 Apr;34(2):153-9. doi: 10.1097/FTD.0b013e31824868f3.

PMID:
22354160
4.

Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.

Sinxadi PZ, Leger PD, McIlleron HM, Smith PJ, Dave JA, Levitt NS, Maartens G, Haas DW.

Br J Clin Pharmacol. 2015 Jul;80(1):146-56. doi: 10.1111/bcp.12590. Epub 2015 May 28.

5.

Effects of CYP2B6 and CYP1A2 Genetic Variation on Nevirapine Plasma Concentration and Pharmacodynamics as Measured by CD4 Cell Count in Zimbabwean HIV-Infected Patients.

Mhandire D, Lacerda M, Castel S, Mhandire K, Zhou D, Swart M, Shamu T, Smith P, Musingwini T, Wiesner L, Stray-Pedersen B, Dandara C.

OMICS. 2015 Sep;19(9):553-62. doi: 10.1089/omi.2015.0104.

6.

Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans.

Haas DW, Gebretsadik T, Mayo G, Menon UN, Acosta EP, Shintani A, Floyd M, Stein CM, Wilkinson GR.

J Infect Dis. 2009 Mar 15;199(6):872-80. doi: 10.1086/597125.

7.

Population pharmacokinetic and pharmacogenetic analysis of nevirapine in hypersensitive and tolerant HIV-infected patients from Malawi.

Dickinson L, Chaponda M, Carr DF, van Oosterhout JJ, Kumwenda J, Lalloo DG, Pirmohamed M, Heyderman RS, Khoo SH.

Antimicrob Agents Chemother. 2014;58(2):706-12. doi: 10.1128/AAC.02069-13. Epub 2013 Nov 11.

8.

Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians.

Brown KC, Hosseinipour MC, Hoskins JM, Thirumaran RK, Tien HC, Weigel R, Tauzie J, Shumba I, Lamba JK, Schuetz EG, McLeod HL, Kashuba AD, Corbett AH.

Pharmacogenomics. 2012 Jan;13(1):113-21. doi: 10.2217/pgs.11.132. Epub 2011 Nov 23.

9.

Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women.

Chantarangsu S, Cressey TR, Mahasirimongkol S, Capparelli E, Tawon Y, Ngo-Giang-Huong N, Jourdain G, Lallemant M, Chantratita W.

J Antimicrob Chemother. 2009 Dec;64(6):1265-73. doi: 10.1093/jac/dkp351. Epub 2009 Oct 6.

10.

Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population.

Mahungu T, Smith C, Turner F, Egan D, Youle M, Johnson M, Khoo S, Back Dj, Owen A.

HIV Med. 2009 May;10(5):310-7. doi: 10.1111/j.1468-1293.2008.00689.x. Epub 2009 Feb 17. Erratum in: HIV Med. 2009 Nov;10(10):661.

11.

CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients.

Chen J, Sun J, Ma Q, Yao Y, Wang Z, Zhang L, Li L, Sun F, Lu H.

Ther Drug Monit. 2010 Oct;32(5):573-8. doi: 10.1097/FTD.0b013e3181ea953c.

PMID:
20625352
12.

CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.

Kwara A, Lartey M, Sagoe KW, Rzek NL, Court MH.

Br J Clin Pharmacol. 2009 Apr;67(4):427-36. doi: 10.1111/j.1365-2125.2009.03368.x.

13.

Clinical and genetic determinants of plasma nevirapine exposure following an intrapartum dose to prevent mother-to-child HIV transmission.

Vardhanabhuti S, Acosta EP, Ribaudo HJ, Severe P, Lalloo U, Kumarasamy N, Taulo F, Kabanda J, Oneko O, Ive P, Sambarey P, Chan ES, Hitti J, Hong F, McMahon D, Haas DW; A5207 ACTG Study Team.

J Infect Dis. 2013 Aug 15;208(4):662-71. doi: 10.1093/infdis/jit223. Epub 2013 May 17.

14.

Integration of population pharmacokinetics and pharmacogenetics: an aid to optimal nevirapine dose selection in HIV-infected individuals.

Schipani A, Wyen C, Mahungu T, Hendra H, Egan D, Siccardi M, Davies G, Khoo S, Fätkenheuer G, Youle M, Rockstroh J, Brockmeyer NH, Johnson MA, Owen A, Back DJ; German Competence Network for HIV/AIDS.

J Antimicrob Chemother. 2011 Jun;66(6):1332-9. doi: 10.1093/jac/dkr087. Epub 2011 Mar 25.

15.

High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients.

Swart M, Skelton M, Ren Y, Smith P, Takuva S, Dandara C.

Pharmacogenet Genomics. 2013 Aug;23(8):415-27. doi: 10.1097/FPC.0b013e328363176f.

PMID:
23778320
16.

Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.

Holzinger ER, Grady B, Ritchie MD, Ribaudo HJ, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford DB, Daar ES, McLaren P, Haas DW.

Pharmacogenet Genomics. 2012 Dec;22(12):858-67. doi: 10.1097/FPC.0b013e32835a450b.

17.

Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices.

Calcagno A, D'Avolio A, Simiele M, Cusato J, Rostagno R, Libanore V, Baietto L, Siccardi M, Bonora S, Di Perri G.

Br J Clin Pharmacol. 2012 Jul;74(1):134-40. doi: 10.1111/j.1365-2125.2012.04163.x.

18.

CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.

Saitoh A, Sarles E, Capparelli E, Aweeka F, Kovacs A, Burchett SK, Wiznia A, Nachman S, Fenton T, Spector SA.

AIDS. 2007 Oct 18;21(16):2191-9.

PMID:
18090046
19.

Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.

Wyen C, Hendra H, Vogel M, Hoffmann C, Knechten H, Brockmeyer NH, Bogner JR, Rockstroh J, Esser S, Jaeger H, Harrer T, Mauss S, van Lunzen J, Skoetz N, Jetter A, Groneuer C, Fätkenheuer G, Khoo SH, Egan D, Back DJ, Owen A; German Competence Network for HIV/AIDS.

J Antimicrob Chemother. 2008 Apr;61(4):914-8. doi: 10.1093/jac/dkn029. Epub 2008 Feb 14.

20.

Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes?

Micheli JE, Chinn LW, Shugarts SB, Patel A, Martin JN, Bangsberg DR, Kroetz DL.

Pharmacogenet Genomics. 2013 Nov;23(11):591-6. doi: 10.1097/FPC.0b013e32836533a5.

Items per page

Supplemental Content

Write to the Help Desk